Tragic Update on French Drug Trial Gone Wrong


A drug trial in France has officially gone from bad to worse.

A drug trial in France has officially gone from bad to worse.

On January 15 we learned that one participant was declared brain dead and five additional participants were hospitalized after taking part in a phase I clinical trial. The trial was testing an experimental molecule for a painkiller, a FAAH enzyme inhibitor. The University Hospital of Rennes revealed that the participant who had been declared brain dead passed away on January 17.

Out of the 128 participants, 90 were given the drug at different dosage levels and the remainder were given a placebo. BIAL, a Portuguese pharmaceutical company, developed the drug and said that 108 patients had used the drug with any moderate or serious problems.

  • MD Magazine is on Facebook, Twitter, Instagram, and LinkedIn!

“Our thoughts and solidarity go out to the family of this volunteer,” a statement from Bial said.

Bial says that they continue to follow the other hospitalized participants and are working with the Health Authorities.

What to Read Next >>> Your Brain Could Be Getting Addicted to That Chronic Pain

Related Videos
How to Adequately Screen for and Treat Cognitive Decline in Primary Care
Tailoring Chest Pain Diagnostics to Patients, with Kyle Fortman, PA-C, MBA
James R. Kilgore, DMSc, PhD, PA-C: Cognitive Decline Diagnostics
Solutions to Prevent Climate Change-Related Illness, with Janelle Bludhorn, PA-C
Kyle Fortman, PA-C, MBA: Troponin and Heart Injury Risk Screening Recommendations
What Should the American Academy of Physician Associates Focus on in 2025?
The Rising Rate of Heat-Related Illness, with Janelle Bludhorn, PA-C
Robert Weinrieb, MD: Psychiatry-Hepatology Approach for Alcohol-Related Liver Disease
Brian Barnett, MD: Psychedelics Fitting into the SUDs Treatment Paradigm
© 2024 MJH Life Sciences

All rights reserved.